Addiction: Brain mechanisms and their treatment implications

Lancet

Volumn 347, Issue 8993, 1996, Pages 31-36

  Nutt, David J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR; CALCIUM CHANNEL; DOPAMINE; ENDORPHIN; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

BRAIN FUNCTION; DRUG DEPENDENCE; DRUG SENSITIZATION; DRUG TOLERANCE; DRUG WITHDRAWAL; EUPHORIA; HUMAN; MAINTENANCE THERAPY; NEUROCHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030045709     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91561-5     Document Type: Article

References (47)

1. Lewis JW. Buprenorphine. Drug Alcohol Dep 1985; 14: 363-72.
2. Busto U, Kaplan HL, Zawertailo L, Seller EM. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 1994; 55: 451-63.
3. Judson BA, Goldstein A. Naltrexone treatment of heroin addiction: one-year follow-up. Drug Alcohol Dep 1984; 13: 357-65.
4. Hunkeler W, Mohler H, Pieri L, et al. Selective antagonists of benzodiazepines. Nature 1981; 290: 515-16.
5. Shimada S, Kitayama S, Lin C, et al. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1992; 254: 576-78.
6. Rothman RB, Mele A, Reid AA, et al. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav 1991; 40: 387-97.
7. Aceto MD, Bowman ER, May EL, et al. Very long-acting narcotic antagonists: the 14B-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneim-Forsch/Drug Res 1989; 39: 570-75.
8. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction 1995; 90: 1179-88.
9. Gawin FH. Cocaine addiction: psychology and neurophysiology. Science 1991; 251: 1580-86.
10. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentration in the mesolimbic system of freely moving rats. Proc Natl Acad Sci 1988; 85: 5274.
11. Hubner CB, Moreton JE. Effects of selective D1 and D2 dopamine antagonists on cocaine self-administration in the rat. Psychopharmacology 1991; 105: 151-56.
12. Goldman D. Dopamine transporter, alcoholism and other diseases. Nature Med 1995; 1: 624-25.
13. Glue P, Nutt DJ. Overexcitement and disinhibition: dynamic neurotransmitter interactions in alcohol withdrawal. Br J Psychiatry 1990; 157: 491-99.
14. Tiihonen J, Kuikka J, Bergström K, et al. Altered striatal dopamine reuptake site densities in habitually violent and non-violent alcoholics. Nature Med 1995; 1: 654-57.
15. Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CH, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994; 165: 515-23.
16. Pike VW. Positron-emitting radioligands for studies in vivo: probes for human psychopharmacology. J Psychopharmacol 1993; 7: 139-58.
17. London ED, Cascella NG, Wong DF, et al. Cocaine-induced reduction of glucose utilization in human brain. Arch Gen Psychiatry 1990; 47: 567-74.
18. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1993; 49: 876-80.
19. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. TIPS 1992; 13: 177-84.
20. Acquas E, Meloni M, Di Chiara G. Blockade of δ-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Eur J Pharmacol 1993; 230: 239-41.
21. Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptide on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 1990; 55: 1743-40.
22. Bartenstein PA, Duncan JS, Prevett MC, et al. Investigation of opioid system in absence seizures with positron emission tomography. J Neurol Neurosurg Psychiatry 1993; 56: 1295-302.
23. Gold MS, Redmond DE, Kleber HD. Clonidine in opiate withdrawal. Lancet 1978; ii: 599-602.
24. Brunning J, Mumford JP, Keaney FP. Lofexidine in alcohol withdrawal states. Alcohol Alcoholism 1986; 21: 167-70.
25. Glue P, Nutt DJ. Clonidine in alcohol withdrawal: a pilot study of differential symptom responses following iv clonidine. Alcohol Alcoholism 1987; 22: 161-66.
26. Borg S, Kvande H, Sedvall G. Central norepinephrine metabolism during alcohol intoxication in addicts and healthy volunteers. Science 1981; 213: 1135-37.
27. McDougle CJ, Black JE, Malison RT, et al. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch Gen Psychiatry 1994; 51: 713-19.
28. 1 adrenergic receptors in the ventral striatum. Neuroscience 1991; 43: 419-28.
29. Pike VW, Hume SP, Aigbirhio F, Turton DR, Nutt DJ. [11-C]RX821002 as potential PET radioligand for central adrenoceptors. J Label Compound Radiopharm 1993; 32: 495-97.
30. Virkkunen M, Rawlings R, Tokola R, et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994; 51: 20-27.
31. Benkelfat C, Murphy DL, Hill JL, George DT, Nutt DJ, Linnoila M. Ethanol-like properties of the serotonin partial agonist m-chlorphenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry 1991; 48: 383.
32. Myers RD, Lankford M, Bjork A. Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide. Pharmacol Biochem Behav 1992; 43: 661-67.
33. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. TIPS 1992; 13: 69-75.
34. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics. Arch Gen Psychiatry 1994; 51: 720-31.
35. 11C]WAY-100635. Eur J Pharmacol 1995; 283: R1-R3.
36. Cowley DS, Roy-Byrne PP, Godon C, et al. Response to diazepam in sons of alcoholics. Alcohol Clin Exp Res 1992; 16: 1057-63.
37. Nutt DJ, Peters TJ. Alcohol: the drug. Br Med Bull 1994; 50: 5-17.
38. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251: 85-87.
39. Persson A, Pauli S, Swahn CG, Halldin C, Sedvall G. Cerebral uptake of [11]C-Ro 15-1788 and its acid metabolite [11]C-Ro 15-3890; PET study in healthy volunteers. Hum Psychopharm 1989; 4: 215-20.
40. Woods SW, Seibyl JP, Goddard AW, et al. Dynamic SPECT imaging after injection of the benzodiazepine receptor ligand [123]lomazenil in healthy human subjects. Psychiatry Res Neuroimaging 1992; 45: 67-77.
41. Malizia AL, Coupland NJ, Nutt DJ. Benzodiazepine receptor function in anxiety disorders. In: Biggio G, Sanna E, Serra M, Costa E, eds. GABA-A receptors and anxiety: from neurobiology to treatment. New York: Raven Press, 1955: 115-33.
42. Pratt JA. Psychotropic drug tolerance and dependence: common underlying mechanisms? In: Pratt J, ed. The biological bases of drug tolerance and dependence. London: Academic Press, 1991: 1-28.
43. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN. Anxiolytic effects of CCK-B antagonists. Neuropeptides 1991; 19 (suppl): 65-73.
44. Abood ME, Martin BR. Neurobiology of marijuana abuse. TIPS 1992; 13: 201-06.
45. Devane WA, Hanus L, Brewer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 158: 1946-49.
46. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett: 1994; 350: 240-44.
47. Little HJ. The role of neuronal calcium channels in dependence of ethanol and other sedatives hypnotics. Pharmac Ther 1991; 50: 347-65.